Cadila Healthcare to sell 49 pc stake in WHPL to Windlas Biotech for Rs 99.44 cr
New Delhi: Drug firm Cadila Healthcare on Thursday said it has signed a definitive pact to sell its 49 per cent stake in Windlas Healthcare to Windlas Biotech for Rs 99.44 crore.
The company's board has approved and signed the agreement for the sale of 2,31,33,717 equity shares of Rs 10 each fully paid-up capital, representing 49 per cent of the total paid-up share capital of Windlas Healthcare Pvt Ltd (WHPL), to Windlas Biotech Pvt Ltd, Cadila Healthcare said in a filing to the BSE.
"Consequent to above divestment and upon completion of the transaction in relation to the sale of the said equity shares, the company shall cease to hold any equity shares in WHPL, it added.
A total of Rs 99,44,07,423 will be received as consideration for the sale, which is expected to be completed within 10 business days, Cadila Healthcare said.
Shares of Cadila Healthcare were trading at Rs 325.95 per scrip on the BSE, down 0.18 per cent from its previous close.
Read also: Treating Coronavirus: Zydus Explores The Biologicals Route With Long-Acting Interferon Alpha-2b
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.